The purpose of this study is to assess the efficacy and safety of reserpine for the treatment of cocaine dependence.
Full Title of Study: “Phase 2, Double-Blind, Placebo-Controlled Trial of Reserpine for the Treatment of Cocaine Dependence”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
To assess the efficacy and safety of reserpine in reducing cocaine use in subjects with cocaine dependence. This is a double-blind, placebo-controlled, parallel-group design with a 2 week baseline period.
- Drug: Reserpine
Clinical Trial Outcome Measures
- Cocaine use
- Addiction severity
- Cocaine withdrawal
- Adverse events
- Clinical improvement
Participating in This Clinical Trial
Be at least 18 yrs of age; DSM-4 diagnosis of cocaine dependence; treatment seeking individuals; have the ability to understand and provide written informed consent; females of child bearing potential using appropriate birth control method Exclusion Criteria:
Additional criteria available during screening at the site.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 99 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Cincinnati VA Medical Center
- Provider of Information About this Clinical Study
- Liza Gorgon / Clinical Trials Specialist, NIDA
- Overall Official(s)
- Eugene Somoza, M.D., Ph.D., Principal Investigator, Cincinnati VA Medical Center
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.